Jeff Anderson Appointed New CEO at Nutjobs Inc.

Nutjobs Inc., a leader in the sustainable plastics industry, is pleased to announce the appointment of Jeff Anderson as its new Chief Executive Officer. Jeff joins Nutjobs with a strong background in leadership and an impressive track record in the biotechnology and sustainability sectors.

Nutjobs manufactures bioplastics using agricultural byproducts, such as almond hulls and shells, as feedstock. The company’s fully compostable products are cost-effective, environmentally sustainable plastic substitutes for a variety of end markets.

With over a decade of experience in successfully bringing novel, bio-derived products to the market, Jeff brings a wealth of expertise to his new role. As the former Chief Operating Officer at Manus Bio, Jeff was instrumental in establishing in-house biomanufacturing both in the United States and abroad, solidifying his reputation as an innovative, results-driven leader.

“We are excited to welcome Jeff Anderson to Nutjobs as our new CEO. His broad experience and tactical leadership will be instrumental in executing against our vision to provide innovative, sustainable solutions to our customers,” said Paul Kephart, Co-Founder, Chief Technology Officer and Chairperson of the Nutjobs Board.

As CEO, Jeff will lead Nutjobs in its continued commitment to delivering high-quality, sustainable materials. His expertise in commercialization, manufacturing and sustainability aligns perfectly with Nutjobs’ core values and future ambitions.

“I am excited to join the Nutjobs team and lead this dynamic and forward-thinking organization,” said Jeff Anderson. “Our commitment to innovative, sustainable solutions and improving the impact of single-use plastics is a vision I wholeheartedly share. I look forward to collaborating with Paul and the team to elevate Nutjobs to new heights.”

Jeff’s appointment as CEO represents an important step in Nutjobs’ ongoing commitment to expanding its impact in the health and wellness industry. His leadership is expected to drive innovation, product development and sustainable practices in the company, making Nutjobs a leader in the field.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”